As of November 7, 2026, 2 holders' latest Schedule 13D or 13G filings report owning 5% or more of Provectus Biopharmaceuticals, Inc. The largest reported stake is Pershing Edward's, at 11.61%. 3 filings are on record since December 1, 2025 (Schedule 13D/A, July 22, 2026).
Sell to companies like Provectus Biopharmaceuticals, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Pershing Edward · Sole voting: 52,278,925 · Shared voting: 162,350 · Sole dispositive: 52,278,925 · Shared dispositive: 162,350 · SCHEDULE 13D/A, 2026-07-22
- · Holder: Dominic Rodrigues · Percent: 5.67% · SCHEDULE 13D
- · Holder: Pershing Edward · Percent: 10.56% · SCHEDULE 13D/A
Provectus Biopharmaceuticals, Inc. has 3 Schedule 13D or 13G filings on record since 2025-12-01. 2 holders' latest filing reports 5% or more of common stock, par value $0.001 per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| 11.61% | 52,441,275 | SCHEDULE 13D/A, 2026-07-22 | 2026-06-30 | |
| 5.67% | 25,220,549 | SCHEDULE 13D, 2025-12-08 | 2025-12-02 |
Holding shares or following this stake? See who's behind Provectus Biopharmaceuticals, Inc. and the warning signs.
Free to see. No signup.
Watch Provectus Biopharmaceuticals, Inc.
Get an email when Provectus Biopharmaceuticals, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Provectus Biopharmaceuticals, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Provectus Biopharmaceuticals, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Provectus Biopharmaceuticals, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
3 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Pershing Edward | 52,278,925 | 162,350 | 52,278,925 | 162,350 | SCHEDULE 13D/A, 2026-07-22 |
The latest filing identifies Provectus Biopharmaceuticals, Inc. by CUSIP 74373P108 and gives its principal executive office as 800 S. GAY STREET, SUITE 1610, KNOXVILLE, TN 37929 (SCHEDULE 13D/A, 2026-07-22).
Source of funds (Item 3)
Item 3 of the Schedule 13D is hereby amended and restated in its entirety as follows: The Issuer has issued an aggregate of $7,512,500 principal amount of secured convertible promissory notes (the "Notes") to the Reporting Person on various dates from April 13, 2018 to May 28, 2026.Pershing Edward, SCHEDULE 13D/A, 2026-07-22
Purpose of Transaction (Item 4)
Dominic Rodrigues
The Reporting Person acquired the securities for investment purposes. In his capacity as a director and executive officer of the Issuer, the Reporting Person may have influence over the corporate activities of the Issuer, including activities which may relate to items described in subparagraphs (a) through (j) of Item 4 of Schedule 13D. Subject to the Issuer's Insider Trading Policy, the Reporting Person may from time to time buy or sell securities of the Issuer as appropriate for his personal circumstances. Except as described herein, the Reporting Person does not have any present plans or proposals that relate to or would result in any of the transactions described in subparagraphs (a) through (j) of Item 4 of Schedule 13D. The Reporting Person may, from time to time, purchase additional securities of the Issuer either in the open market or in privately-negotiated transactions, depending upon the Reporting Person's evaluation of the Issuer's business, prospects and financial condition, the market for such securities, other opportunities available to the Reporting Person, general economic conditions, stock market conditions and other factors. Depending upon the factors noted above, the Reporting Person may also decide to hold or dispose of all or part of his investments in securities of the Issuer.Item 4 of the SCHEDULE 13D filed 2025-12-08
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-12-01 | Pershing Edward | 10.56% | SCHEDULE 13D/A |
| 2025-12-08 | Dominic Rodrigues | 5.67% | SCHEDULE 13D |
| 2026-07-22 | Pershing Edward | 11.61% | SCHEDULE 13D/A |
Questions about who owns Provectus Biopharmaceuticals, Inc.
Who owns Provectus Biopharmaceuticals, Inc.?
On this page, 2 holders' latest ownership filings report 5% or more of Provectus Biopharmaceuticals, Inc.: Pershing Edward (11.61%, Schedule 13D/A, filed 2026-07-22) and Dominic Rodrigues (5.67%, Schedule 13D, filed 2025-12-08).
Who are the largest shareholders of Provectus Biopharmaceuticals, Inc.?
By the share each holder's latest filing reports, the largest holders of Provectus Biopharmaceuticals, Inc. on this page are Pershing Edward (11.61%) and Dominic Rodrigues (5.67%).
When did Pershing Edward buy into Provectus Biopharmaceuticals, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Pershing Edward on this page is the Schedule 13D/A, filed 2025-12-01, reporting 10.56%; its latest, Schedule 13D/A filed 2026-07-22, reports 11.61%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 3 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Tools for this story
Each opens in a new tab, filled in for Provectus Biopharmaceuticals, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.